


# • Planning Committee and Speaker Disclosures

Name	Brian Bressler	Jan Dutz	Yvette Leung	Charles Lynde	Janet Pope
<b>Direct financial payments including honoraria</b>	AbbVie, Amgen, AMT, BMS, CCRN, Celgene, Ferring, Fresenius Kabi, Genetech, Gilead, Janssen, Merck, Novartis, Pfizer, Protagonist, Sandoz, Takeda	CCRN	AbbVie, Janssen, Takeda, Pfizer, CCRN	CCRN	CCRN
<b>Advisory boards/ speakers' bureaus</b>	None	AbbVie, Amgen, Bausch, Celgene, Leo, Janssen, Novartis, Sanofi	AbbVie, Janssen, Takeda, Pfizer, BMS	AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch, Bayer, BI, BMS, Celgene, Cipher, Dermavant, Eli Lilly, Fresenius Kabi, GSK, Innovaderm, Intega Skin, Janssen, Kyowa, La Roshe Posay, LEO Pharma, L'Oreal, Medexus, Merck, P&G, Pediapharm, Regeneron, Roche, Sanofi Genzyme, Sentrex, TEVA, Tribute, UCB, Valeant, Viatrix, Volo Health	AbbVie, Amgen, BMS, BI, Celltrion, Emerald Pharma, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Mallinckrodt Pharmaceuticals, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, Viatrix, UCB
<b>Funded grants/ clinical trials</b>	None	Corbus, Eli Lilly and Company	AbbVie, BMS	AbbVie, Amgen, Aralez, Arcutis, Bausch, Bayer, BI, BMS, Celgene, Cipher, Dermavant, Eli Lilly, GSK, Innovaderm, Janssen, Kyowa, LEO Pharma, L'Oreal, Merck, Pediapharm, Regeneron, Roche, Sanofi Genzyme, Tribute, UCB, Valeant	AbbVie, Bayer, BI, BMS, Fresenius Kabi, Lilly, Mallinckrodt Pharmaceuticals, Merck, Roche, Seattle Genetics
<b>Patents</b>	None	None	None	None	None
<b>Other</b>	None	Solius Inc.	None	None	None

## Disclosure of Financial Support



This program has received financial support from Organon Canada Inc. in the form of educational funding.

This program has received in-kind support from Organon Canada Inc. in the form of logistical support.

Potential for conflict(s) of interest:

Drs. Brian Bressler, Charles Lynde and Janet Pope have received honoraria from the Canadian Collaborative Research Network for this program.

Organon Canada Inc. benefits from the sale of products that will be discussed in this program.

Description of diagnostic and therapeutic options use generic names and do not reflect exclusivity or Branding.

# Mitigating Potential Bias

## Potential for bias was mitigated using the following process:

1. Conflict of interest disclosures for the SPC and speakers were reviewed and approved by the SPC.
2. If any potential conflicts of interest had been identified for a member of the SPC, the member would recuse himself or herself from planning decisions relevant to the identified conflict.
3. If a conflict of interest is identified for a potential speaker, the speaker will be required to limit their presentation to a discussion of the evidence and avoid making personal recommendations. If the conflict cannot be mitigated, the speaker will not be approved to present the program.

SPC: Scientific Planning Committee.

